Absci to Participate in Upcoming Investor Conferences
Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced its participation in two upcoming investor conferences in April 2025: H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced its participation in two upcoming investor conferences in April 2025:
- H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference - Fireside chat scheduled for Wednesday, April 2 at 10:30 a.m. ET / 7:30 a.m. PT
- 24th Annual Needham Virtual Healthcare Conference - Fireside chat scheduled for Tuesday, April 8 at 3:45 p.m. ET / 12:45 p.m. PT
Investors and interested parties can access both live and archived webcasts of these fireside chat sessions through Absci's investor relations website at investors.absci.com.
Details
News Market Reaction – ABSI
The recorded move for ABSI in the trading session of this news was -5.54%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.
- H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
Fireside chat on Wednesday, April 2 at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time
- 24th Annual Needham Virtual Healthcare Conference
Fireside chat on Tuesday, April 8 at 3:45 p.m. Eastern Time / 12:45 p.m. Pacific Time
Interested parties may access live and archived webcasts of the fireside chat sessions on the company’s investor relations website at: investors.absci.com.
About Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
Media Contact
press@absci.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.